Nitromemantine Explained
Nitromemantine (developmental code names YQW-36 and EM-036), also known as NitroSynapsin, is a derivative of memantine developed in 2006 for the treatment of Alzheimer's disease. It has been shown to reduce excitotoxicity mediated by over-activation of the glutamatergic system, by blocking NMDA receptors.[1] [2] [3] It was being developed for treatment of Alzheimer's disease and pervasive developmental disorders like autism, but development was discontinued in 2023.[4]
Pharmacology
Like memantine, nitromemantine is a low-affinity voltage-dependent uncompetitive antagonist at glutamatergic NMDA receptors, however nitromemantine selectively inhibits extrasynaptic NMDA receptors while sparing normal physiological synaptic NMDA receptor activity, resulting in less side effects and a greater neuroprotective action, as well as stimulating regrowth of synapses with prolonged administration. The discoverers of nitromemantine have demonstrated that the amyloid-β peptide associated with Alzheimer's disease acts as an agonist at α7 nicotinic acetylcholine receptors, chronic overstimulation of which then results in uncontrolled release of glutamate, and consequent excitotoxicity. By blocking extrasynaptic NMDA receptors, nitromemantine is able to largely prevent this excitotoxicity while minimising the side effects usually seen with less selective NMDA antagonists.[5] The nitrate group of nitromemantine was found to bind to a second site on the extrasynaptic NMDA receptor which had previously been targeted with nitroglycerin, and this double action is thought to be responsible for the increased effectiveness of nitromemantine.[6]
See also
Notes and References
- Lipton SA . Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond . Nature Reviews. Drug Discovery . 5 . 2 . 160–70 . February 2006 . 16424917 . 10.1038/nrd1958 . 2006NRvDD...5..160L . 21379258 .
- Nakamura T, Lipton SA . Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies . Cell Calcium . 47 . 2 . 190–7 . February 2010 . 20060165 . 2875138 . 10.1016/j.ceca.2009.12.009 .
- Labra SR, Compher J, Prabhavalkar A, Almaraz M, Kwong CC, Baal C, Talantova M, Dolatabadi N, Piña-Sanz J, Wang Y, Yoon L, Ghatak S, Gao Z, Zhang Y, Trudler D, Massey L, Lin W, Balistreri A, Bula M, Schork NJ, Mondala TS, Head SR, Kelly JW, Lipton SA . Autophagy activators normalize aberrant Tau proteostasis and rescue synapses in human familial Alzheimer's disease iPSC-derived cortical organoids . July 2025 . 10.1101/2025.06.25.661453 . S.A.L discloses that he is an inventor on worldwide patents for the use of memantine and NitroSynapsin (aka NitroMemantine, YQW-036, or EM-036) for neurodegenerative and neurodevelopmental disorders..
- Web site: EM 036 . AdisInsight . 20 February 2023 . 26 January 2026.
- Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Piña-Crespo JC, Lipton SA . 6 . Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss . Proceedings of the National Academy of Sciences of the United States of America . 110 . 27 . E2518-27 . July 2013 . 23776240 . 3704025 . 10.1073/pnas.1306832110 . 2013PNAS..110E2518T . free .
- Web site: Reversing the loss of brain connections in Alzheimer's disease. . Bruce . Lieberman . vanc . Beaker . Sanford-Burnham Science Blog . June 17, 2013 . September 9, 2013 . September 17, 2013 . https://web.archive.org/web/20130917075618/http://beaker.sanfordburnham.org/2013/06/reversing-the-loss-of-brain-connections-in-alzheimers-disease/ . dead .